Our data provide one of the possible explanations for this—anti-EGFR therapy is supposed to show good therapeutic effect if the EGFR is up-regulated in tumor tissue, but we did not find any up-regulation of EGFR in CRC irrespective of the KRAS mutation status; rather, we found that there was non-significant down-regulation. This evidence concerns the gene KRAS and neoplasm.